ACON vs. NVTA, OPGN, CMND, BPTH, RSLS, HSTO, NMRD, NAOV, SLRX, and ISPC
Should you be buying Aclarion stock or one of its competitors? The main competitors of Aclarion include Invitae (NVTA), OpGen (OPGN), Clearmind Medicine (CMND), Bio-Path (BPTH), ReShape Lifesciences (RSLS), Histogen (HSTO), Nemaura Medical (NMRD), NanoVibronix (NAOV), Salarius Pharmaceuticals (SLRX), and iSpecimen (ISPC). These companies are all part of the "medical" sector.
Invitae (NYSE:NVTA) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, community ranking, profitability, earnings and institutional ownership.
Invitae has a beta of 1.59, indicating that its share price is 59% more volatile than the S&P 500. Comparatively, Aclarion has a beta of 0.44, indicating that its share price is 56% less volatile than the S&P 500.
61.3% of Invitae shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 0.7% of Invitae shares are owned by insiders. Comparatively, 22.3% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Invitae had 8 more articles in the media than Aclarion. MarketBeat recorded 10 mentions for Invitae and 2 mentions for Aclarion. Invitae's average media sentiment score of 0.72 beat Aclarion's score of 0.16 indicating that Aclarion is being referred to more favorably in the news media.
Invitae received 450 more outperform votes than Aclarion when rated by MarketBeat users. However, 100.00% of users gave Aclarion an outperform vote while only 60.95% of users gave Invitae an outperform vote.
Invitae has a net margin of -299.14% compared to Invitae's net margin of -6,480.47%. Invitae's return on equity of -724.93% beat Aclarion's return on equity.
Invitae currently has a consensus price target of $1.00, indicating a potential upside of 11,011.11%. Given Aclarion's higher possible upside, research analysts clearly believe Invitae is more favorable than Aclarion.
Aclarion has lower revenue, but higher earnings than Invitae.
Summary
Invitae beats Aclarion on 8 of the 14 factors compared between the two stocks.
Get Aclarion News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aclarion Competitors List
Related Companies and Tools
